中国阻断乙型肝炎病毒母婴传播的抗病毒治疗策略考量
结果表明,识别高危孕妇并给予抗病毒治疗以阻断围产期HBV传播可行且具成本效果,中国应紧急探索政策方案以实现2030年儿童HBV患病率降至0.1%的消除目标。
要点
- 尽管有免疫预防,2015年估计仍发生51478例围产期HBV传播,均来自HBsAg和HBeAg双阳性母亲。
核心结论
- 识别高危孕妇并给予抗病毒治疗以阻断围产期HBV传播是可行且具成本效果的。
- 中国应紧急探索政策方案,以实现2030年儿童HBV患病率降至0.1%的消除目标。
主要发现
- 尽管有免疫预防,2015年估计发生51478例围产期HBV传播,均来自HBsAg和HBeAg双阳性母亲。
- 假设HBV病毒载量检测可用并指导治疗、所有病毒载量>200000 IU/ml的孕妇均接受治疗,可避免25912例感染,每避免一例感染的成本为3500美元。
关键数值与推荐
- 以HBV病毒载量>200000 IU/ml指导治疗并治疗所有达标孕妇,可避免25912例感染,每避免一例感染的成本为3500美元。
临床怎么用
- 识别高危孕妇并给予抗病毒治疗以阻断围产期HBV传播是可行且具成本效果的。
- 中国应紧急探索政策方案,以实现2030年儿童HBV患病率降至0.1%的消除目标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treating high-risk women with antivirals in their third trimester is a promising intervention to further reduce perinatal transmission in neonates born to hepatitis B surface antigen positive [HBsAg(+)] mothers. METHODS: We estimated the number of perinatal infections based on coverage and effectiveness of hepatitis B immunization. We compared cost-effectiveness of different approaches to identify high-risk women for antiviral treatment, by region and urban/rural residence. RESULTS: Of the 16.59 million live births in 2015, 1.04 million infants (6.3%) were born to HBsAg(+) mothers and 268 201 infants (1.6%) to HBsAg(+) and HBeAg(+) dual-positive mothers. Despite immunoprophylaxis, 51 478 perinatal hepatitis B virus (HBV) transmissions were estimated to have occurred from HBsAg and HBeAg dual-positive mothers in 2015. Using HBeAg or HBV viral load testing to identify high-risk pregnant women and to treat them with Tenofovir, the incremental cost ranged from US$68.2 million to US$90.3 million. Assuming HBV viral load testing is available and used to guide treatment and all women with HBV viral loads >200 000 IU/ml are treated, 25 912 infections would be averted at a projected cost of US$3500 per infection averted. CONCLUSIONS: Identifying high-risk pregnant women and providing them with antiviral treatment is feasible and cost-effective to interrupt perinatal HBV transmissions. Policy options should be urgently explored in order for China to reach the HBV elimination goal of 0.1% prevalence among children by 2030.
引用
- Cui F, Woodring J, Chan P, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. Int J Epidemiol. 2018. PMID: 29757383. doi:10.1093/ije/dyy077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。